Clinical and adipocytokine changes after bariatric surgery in morbidly obese women

Obesity

Volumn 22, Issue 1, 2014, Pages 188-194

  Auguet, Teresa ^a,b   Terra, Ximena ^a   Hernández, Mercè ^c   Sabench, Fàtima ^c   Porras, Jose Antonio ^b   Orellana Gavaldà, Josep Maria ^a   Llutart, Jordi ^b   Guiu Jurado, Esther ^a   Berlanga, Alba ^a   Martinez, Salomé ^b   Aguilar, Carmen ^a   Castillo, Daniel Del ^c   Richart, Cristòbal ^a,b  

^a UNIVERSITAT ROVIRA I VIRGILI   (Spain)

^b HOSPITAL UNIVERSITARI JOAN XXIII   (Spain)

^c HOSPITAL UNIVERSITARI SANT JOAN DE REUS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; C REACTIVE PROTEIN; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; HIGH MOLECULAR WEIGHT ADIPONECTIN; INSULIN; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BARIATRIC SURGERY; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MORBID OBESITY; OUTCOME ASSESSMENT; POSTOPERATIVE PERIOD; PREOPERATIVE EVALUATION; PROGNOSIS; TREATMENT RESPONSE;

ADIPOKINES; ADULT; ANIMALS; BARIATRIC SURGERY; BIOLOGICAL MARKERS; BLOOD GLUCOSE; BODY MASS INDEX; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; CHOLESTEROL, HDL; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INSULIN; INSULIN RESISTANCE; MIDDLE AGED; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; OBESITY, MORBID; POSTOPERATIVE PERIOD; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; TRIGLYCERIDES;

EID: 84892364298     PISSN: 19307381     EISSN: 1930739X     Source Type: Journal    
DOI: 10.1002/oby.20470     Document Type: Article

References (23)

1. Magee C, Barry J, Arumugasamy M, et al. Laparoscopic sleeve gastrectomy for high-risk patients: weight loss and comorbidity improvement-short-term results. Obes Surg 2011; 21: 547-550.
2. Gass M, Beglinger C, Peterli R,. Metabolic surgery-principles and current concepts. Langenbecks Arch Surg 2011; 396: 949-972.
3. Czupryniak L, Pawlowski M, Kumor A, et al. Predicting maximum Roux-en-Y gastric bypass-induced weight reduction-preoperative plasma leptin or body weight? Obes Surg. 2007; 17: 162-167.
4. Zimmet P, Alberti KG,. Surgery or medical therapy for obese patients with Type 2 diabetes? N Engl J Med 2012; 366: 1635-1636.
5. Schauer PR, Kashyap SR, Wolski K, et al. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med 2012; 366: 1567-1576.
6. Mingrone G, Panunzi S, De Gaetano A, et al. Bariatric surgery versus conventional medical therapy for Type 2 diabetes. N Engl J Med 2012; 366: 1577-1585.
7. Carlsson LMS, Peltonen M, Ahlin S, et al. Bariatric surgery and prevention of Type 2 diabetes in Swedish obese subjects. N Engl J Med 2012; 367: 695-704.
8. Jacobs DO,. Bariatric surgery-from treatment of disease to prevention? N Engl J Med 2012; 367: 764-765.
9. Mitterberger MC, Mattesich M, Klaver E, et al. Adipokine profile and insulin sensitivity in formerly obese women subjected to bariatric surgery or diet-induced long-term caloric restriction. J Gerontol A Biol 2010; 65: 915-923.
10. Swarbrick M, Stanhope K, Austrheim-Smith I, et al. Longitudinal changes in pancreatic and adipocyte hormones following Roux-en-Y gastric bypass surgery. Diabetologia 2008; 51: 1901-1911.
11. Woelnerhanssen B, Peterli R, Steinert RE, et al. Effects of postbariatric surgery weight loss on adipokines and metabolic parameters: comparison of laparoscopic roux-en-Y gastric bypass and laparoscopic sleeve gastrectomy-a prospective randomized trial. Surg Obes Relat Dis 2011; 7: 561-568.
12. Auguet T, Terra X, Porras JA, et al. Plasma visfatin levels and gene expression in morbidly obese women with associated fatty liver disease. Clin Biochem 2013; 46: 202-208.
13. Terra X, Auguet T, Quesada I, et al. Increased levels and adipose tissue expression of visfatin in morbidly obese women. The relationship with pro-inflammatory cytokines. Clin Endocrinol 2012; 77: 691-698.
14. Chu SH, Lee MK, Ahn KY, et al. Chemerin and adiponectin contribute reciprocally to metabolic syndrome. PLoS One 2012; 7: e34710.
15. Galic S, Oakhill JS, Steinberg GR,. Adipose tissue as an endocrine organ. Mol Cell Endocrinol 2010; 316: 129-139.
16. Wallace TM, Levy JC, Matthews DR,. Use and abuse of HOMA modeling. Diabetes Care 2004; 27: 1487-1495.
17. Felberbauer F, Langer F, Shakeri-Manesch S, et al. Laparoscopic sleeve gastrectomy as an isolated bariatric procedure: intermediate-term results from a large series in three Austrian centers. Obes Surg 2008; 18: 814-818.
18. Brunner EJ, Kivimäki M, Witte DR, et al. Inflammation, insulin resistance, and diabetes. Mendelian randomization using CRP haplotypes points upstream. PLoS Med 2008; 5: e155.
19. Hofsø D, Ueland T, Hager H, et al. Inflammatory mediators in morbidly obese subjects: associations with glucose abnormalities and changes after oral glucose. Eur J Endocrinol 2009; 161: 451-458.
20. Brethauer S, Heneghan H, Eldar S, et al. Early effects of gastric bypass on endothelial function, inflammation, and cardiovascular risk in obese patients. Surg Endosc 2011; 25: 2650-2659.
21. Sesti G, Folli F, Perego L, Hribal ML, Pontiroli AE,. Effects of weight loss in metabolically healthy obese subjects after laparoscopic adjustable gastric banding and hypocaloric diet. PLoS One 2011; 6: e17737.
22. Weisberg SP, McCann D, Desai M, et al. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003; 112: 1796-1808.
23. Klöting N, Fasshauer M, Dietrich A, et al. Insulin-sensitive obesity. Am J Physiol Endocrinol Metab 2010; 299: E506-E515.